Guerbet Receives FDA Approval for a New Manufacturing Plant for Lipiodol® (ethiodized oil) Injection

19.02.2014 15:55

Guerbet LLC, USA (February 19, 2014)

Princeton, NJ - Guerbet (GBT), the contrast agent specialist for medical imaging, today announced that it had received approval from the U.S. Food and Drug Administration (FDA) for a new manufacturing plant for Lipiodol® (ethiodized oil) Injection, in Montreal, Canada. 

 Click here for press release.